M. Kulyk & Associates LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 3.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,855 shares of the company’s stock after selling 150 shares during the quarter. M. Kulyk & Associates LLC’s holdings in Johnson & Johnson were worth $598,000 at the end of the most recent reporting period.
A number of other hedge funds have also added to or reduced their stakes in JNJ. Federated Hermes Inc. boosted its holdings in shares of Johnson & Johnson by 28.4% during the 1st quarter. Federated Hermes Inc. now owns 738,029 shares of the company’s stock valued at $114,394,000 after buying an additional 163,449 shares in the last quarter. YHB Investment Advisors Inc. boosted its holdings in shares of Johnson & Johnson by 1.5% during the 1st quarter. YHB Investment Advisors Inc. now owns 65,999 shares of the company’s stock valued at $10,230,000 after buying an additional 994 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Johnson & Johnson by 4.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 970,695 shares of the company’s stock valued at $150,458,000 after buying an additional 41,055 shares in the last quarter. Harvey Investment Co. LLC boosted its holdings in shares of Johnson & Johnson by 1.6% during the 1st quarter. Harvey Investment Co. LLC now owns 227,970 shares of the company’s stock valued at $35,335,000 after buying an additional 3,554 shares in the last quarter. Finally, Truepoint Inc. boosted its holdings in shares of Johnson & Johnson by 30.8% during the 1st quarter. Truepoint Inc. now owns 3,521 shares of the company’s stock valued at $546,000 after buying an additional 829 shares in the last quarter. 67.57% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on JNJ. JPMorgan Chase & Co. boosted their target price on shares of Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a report on Friday, July 21st. Raymond James upped their price target on shares of Johnson & Johnson from $181.00 to $184.00 and gave the stock an “outperform” rating in a research note on Monday, July 24th. Atlantic Securities upped their price target on shares of Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a research note on Friday, August 4th. Credit Suisse Group upped their price target on shares of Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. Finally, StockNews.com initiated coverage on shares of Johnson & Johnson in a research note on Thursday, May 18th. They issued a “strong-buy” rating on the stock. Eight research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $171.80.
Johnson & Johnson Price Performance
NYSE JNJ opened at $172.92 on Wednesday. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $181.04. The firm has a market capitalization of $449.41 billion, a P/E ratio of 35.00, a PEG ratio of 2.92 and a beta of 0.54. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.44. The company has a 50-day moving average price of $165.50 and a 200-day moving average price of $161.20.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.62 by $0.18. The business had revenue of $25.53 billion during the quarter, compared to analyst estimates of $24.63 billion. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The company’s revenue was up 6.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.59 earnings per share. Equities research analysts anticipate that Johnson & Johnson will post 10.75 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be paid a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 2.75%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.
Insider Transactions at Johnson & Johnson
In other Johnson & Johnson news, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the sale, the insider now directly owns 87,747 shares in the company, valued at approximately $15,092,484. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, insider William Hait sold 14,698 shares of the stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the transaction, the insider now directly owns 87,747 shares in the company, valued at approximately $15,092,484. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the sale, the executive vice president now directly owns 65,934 shares in the company, valued at approximately $10,549,440. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 47,163 shares of company stock valued at $7,928,856. 0.20% of the stock is currently owned by corporate insiders.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- Are Penny Stocks a Good Fit for Your Portfolio?
- On Holding Slips Into A More Comfortable Price Point
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- 3 Growing Cannabis Stocks Ready To Bloom
- Stock Average Calculator
- Will Meta’s Pullback Offer Buy Point After AI-Driven Surge?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
